Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reply

Val Gebski, Teppo Huttunen, Heikki Joensuu

Research output: Contribution to journalLetterScientific

Original languageEnglish
JournalJAMA Oncology
Volume5
Issue number1
Pages (from-to)118-118
Number of pages1
ISSN2374-2437
DOIs
Publication statusPublished - Jan 2019
MoE publication typeB1 Journal article

Fields of Science

  • SURVIVAL
  • 3122 Cancers

Cite this

@article{7c3cd88a325e4a5e8340fa3a3ce4e653,
title = "Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reply",
keywords = "SURVIVAL, 3122 Cancers",
author = "Val Gebski and Teppo Huttunen and Heikki Joensuu",
year = "2019",
month = "1",
doi = "10.1001/jamaoncol.2018.5739",
language = "English",
volume = "5",
pages = "118--118",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "1",

}

Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reply. / Gebski, Val; Huttunen, Teppo; Joensuu, Heikki.

In: JAMA Oncology, Vol. 5, No. 1, 01.2019, p. 118-118.

Research output: Contribution to journalLetterScientific

TY - JOUR

T1 - Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reply

AU - Gebski, Val

AU - Huttunen, Teppo

AU - Joensuu, Heikki

PY - 2019/1

Y1 - 2019/1

KW - SURVIVAL

KW - 3122 Cancers

U2 - 10.1001/jamaoncol.2018.5739

DO - 10.1001/jamaoncol.2018.5739

M3 - Letter

VL - 5

SP - 118

EP - 118

JO - JAMA Oncology

JF - JAMA Oncology

SN - 2374-2437

IS - 1

ER -